Shares of Hikma Pharmaceuticals Plc (LON:HIK) have received a consensus rating of “Buy” from the ten brokerages that are presently covering the stock. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is GBX 2,322.88 ($29.19).
Several analysts have recently weighed in on HIK shares. Numis Securities Ltd cut shares of Hikma Pharmaceuticals Plc to an “add” rating and set a GBX 2,350 ($29.53) price objective on the stock. in a research report on Friday, March 10th. Peel Hunt restated a “buy” rating and set a GBX 2,340 ($29.41) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Friday, February 24th. Jefferies Group LLC raised their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,065 ($25.95) to GBX 2,162 ($27.17) and gave the company a “buy” rating in a research report on Tuesday, January 17th. AlphaValue restated a “buy” rating and set a GBX 2,431 ($30.55) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, November 30th. Finally, JPMorgan Chase & Co. cut shares of Hikma Pharmaceuticals Plc to a “neutral” rating and raised their price objective for the company from GBX 2,100 ($26.39) to GBX 2,400 ($30.16) in a research report on Thursday, March 16th.
Hikma Pharmaceuticals Plc (LON:HIK) opened at 1990.00 on Tuesday. The firm’s market cap is GBX 4.78 billion. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,575.00 and a 12 month high of GBX 2,703.00. The stock has a 50 day moving average price of GBX 2,070.89 and a 200 day moving average price of GBX 1,920.87.
The firm also recently announced a dividend, which will be paid on Thursday, May 25th. Investors of record on Thursday, April 6th will be issued a dividend of GBX 0.22 ($0.00) per share. The ex-dividend date is Thursday, April 6th. This represents a dividend yield of 0.78%. This is a positive change from Hikma Pharmaceuticals Plc’s previous dividend of $0.21.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Mideast Time and is the sole property of of Mideast Time. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.mideasttime.com/hikma-pharmaceuticals-plc-hik-given-average-recommendation-of-buy-by-analysts/1590110.html.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.